Compare Centrus Energy Corp (LEU) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centrus Energy Corp vs Neurocrine Biosciences Inc — how do they compare? Centrus Energy Corp trades at $142.44 (market cap $2.91B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 4.9× Centrus Energy Corp's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Centrus Energy Corp for 29 Days and Neurocrine Biosciences Inc for 23 Days on average.
| LEU | NBIX | |
|---|---|---|
Market Cap | $2.91B | $14.36B |
Volume | 903,777 | 1,237,180 |
Sector | Energy | Health |
52-Week High | $436.00 | $185.50 |
52-Week Low | $138.18 | $123.10 |
Typical Hold Time | 29 Days | 23 Days |
Enterprise Value | $2.22B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $142.44, down 3.19% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows elevated valuation metrics (P/E 75.18, P/S 6.68) while profitability metrics remain solid (net margin 10.23%, ROE 8.05%). Recent news highlights the company's strategic position as a key HALEU supplier amid growing nuclear energy demand, with multiple new supply contracts announced in September 2026.
LEU presents a high-risk, high-reward opportunity with analyst consensus price target of $218.10 (53% upside) but significant execution risks. The company's growth depends on successful expansion of domestic uranium enrichment capacity and capitalizing on nuclear energy tailwinds, though recent profit margin compression and negative operating cash flow projections for 2026 warrant caution.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
